

Research Article

Inflammatory Serum Protein Profiling of Patients with Lumbar Radicular Pain One Year after Disc Herniation

Aurora Moen,^{1,2} Anne-Li Lind,³ Måns Thulin,⁴ Masood Kamali-Moghaddam,⁵
Cecilie Røe,^{2,6} Johannes Gjerstad,^{1,2,7} and Torsten Gordh³

¹National Institute of Occupational Health, 0033 Oslo, Norway

²Department of Physical Medicine and Rehabilitation, Oslo University Hospital, 0424 Oslo, Norway

³Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden

⁴Department of Statistics, Uppsala University, 751 20 Uppsala, Sweden

⁵Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden

⁶Faculty of Medicine, University of Oslo, 0316 Oslo, Norway

⁷Department of Molecular Biosciences, University of Oslo, 0371 Oslo, Norway

Correspondence should be addressed to Johannes Gjerstad; johannes.gjerstad@stami.no

Received 4 January 2016; Revised 22 March 2016; Accepted 19 April 2016

Academic Editor: Sarah Howie

Copyright © 2016 Aurora Moen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Earlier studies suggest that lumbar radicular pain following disc herniation may be associated with a local or systemic inflammatory process. In the present study, we investigated the serum inflammatory protein profile of such patients. All 45 patients were recruited from Oslo University Hospital, Ullevål, Norway, during the period 2007–2009. The new multiplex proximity extension assay (PEA) technology was used to analyze the levels of 92 proteins. Interestingly, the present data showed that patients with radicular pain 12 months after disc herniation may be different from other patients with regard to many measurable serum cytokines. Given a false discovery rate (FDR) of 0.10 and 0.05, we identified 41 and 13 proteins, respectively, which were significantly upregulated in the patients with severe pain one year after disc herniation. On the top of the list ranked by estimated increase we found C-X-C motif chemokine 5 (CXC5; 217% increase), epidermal growth factor (EGF; 142% increase), and monocyte chemoattractant protein 4 (MCP-4; 70% increase). Moreover, a clear overall difference in the serum cytokine profile between the chronic and the recovered patients was demonstrated. Thus, the present results may be important for future protein serum profiling of lumbar radicular pain patients with regard to prognosis and choice of treatment. We conclude that serum proteins may be measurable molecular markers of persistent pain after disc herniation.

1. Introduction

Lumbar radicular pain, also referred to as “sciatica,” is characterized by radiating pain that typically follows the dermatome of the affected nerve-root. When strict criteria are used, the prevalence rate is approximately 2% [1, 2]. Roughly 90% of the lumbar radicular pain cases are caused by intervertebral disc herniation with nerve-root compression [3]. Although a spontaneous recovery is seen in most of these patients, only 30% are completely pain-free one year after onset [4]. At present, there are no measurable molecular markers for patient prognosis, choice of treatment, or development of new compounds for persistent pain after disc herniation.

Earlier studies suggest that leakage of nucleus pulposus into the spinal canal after disc herniation may initiate immunological and inflammatory responses close to the nerve-roots [5, 6] that increase the activity in nociceptive pathways [7–11]. This inflammatory influence has been attributed to an upregulation of interleukins (ILs), tumor necrosis factor (TNF), matrix metalloproteinases (MMPs), nitric oxide (NO), and prostaglandins (PGs) in or around the herniated disc [12–14].

In addition, recent data point to increased levels of circulating cytokines in patients with chronic pain. For example, higher systemic IL-2 and TNF levels have been observed in patients with painful neuropathies compared to painless

neuropathies [15]. Moreover, IL-6 and IL-8 appear to be elevated in serum of patients with radicular pain due to disc herniation [16, 17]. Thus, earlier observations suggest that disc herniation may be associated with an upregulation of several inflammatory molecules. In these previous studies, however, the methodological hindrance has limited the number of markers to a few proteins.

In the present study, in contrast, we take advantage of the new multiplex proximity extension assay (PEA) technology to simultaneously analyze the levels of 92 inflammatory proteins [18]. To adjust for multiplicity, we used the false discovery rate (FDR) approach in the statistical analysis of the data [19]. The aim of the present study was to investigate if it is possible to define an inflammatory fingerprint in the serum of patients with persistent lumbar radicular pain after disc herniation. Our results indicate that the PEA technology may be important for future protein serum profiling of lumbar radicular pain patients with regard to prognosis and choice of treatment.

2. Materials and Methods

2.1. Patients. Patients with lumbar radicular pain were recruited from the outpatient clinic at Oslo University Hospital, Ullevål, Norway, during the period 2007–2009. The inclusion criteria were age between 18 and 60 years, lumbar disc herniation confirmed by magnetic resonance imaging (MRI) with corresponding radicular pain, and positive Straight Leg Raising (SLR). The exclusion criteria were lumbar spinal stenosis, previous surgery for herniated disc at the same level or fusion at any level in lumbar spine, generalized musculoskeletal pain, inflammatory rheumatic disease, diabetic polyneuropathy, cardiovascular disease (NYHA III and IV), cancer, psychiatric disease, cauda equine syndrome, alcohol or drug abuse, recent surgery (within one month), pregnancy, poor Norwegian language, or non-European-Caucasian ethnicity. In total, 122 patients (82%) of the 148 patients who met the eligibility requirement were included in the intended follow-up assessment.

Surgical treatment was given to patients with persistent radicular pain lasting for more than 8 weeks, neurological deficits (sensory changes, muscle weakness, and depressed or absent deep tendon reflexes), and corresponding magnetic resonance imaging findings in the anticipated location. Patients who did not clearly fulfill these criteria were managed conservatively by a treatment comprised of a brief cognitive intervention, activity guidance during the acute phase of disc herniation, and, for the majority of patients, physiotherapy.

At inclusion, at 6 weeks and at 12-month follow-up, the patients were asked to rate their pain intensity in activity during the last week on a 10 cm visual analog scale (VAS) with endpoints “no pain” and “worst possible pain.” Hopkins symptom checklist (HSCL), a 25-item questionnaire, was used to register psychological distress, that is, anxiety and depression. The drop-out rate was 8% and ultimately, 112 patients were assessed at 12-month follow-up.

Among these 112 patients, patients with VAS > 6 at 12-month follow-up were defined as a high pain group

($n = 23$). Moreover, a gender and age matched sample from the same 112 patients with VAS < 1 at 12-month follow-up was defined as a low pain group ($n = 22$). The serum levels in inflammatory-related proteins in the high pain group versus the low pain group were analyzed. All participants received written information and signed an informed consent form. The study was approved by the Norwegian Regional Committee for Medical Research Ethics and the Norwegian Social Science Data Services.

2.2. Blood Sampling. At 12-month follow-up, venous blood was collected and kept on ice for 45 minutes. After centrifugation at 2,000 g for 10 min at 4°C, the supernatant serum was collected and stored in aliquots at –80°C until further analysis. Serum was used to analyze the biomarkers for the levels of 92 inflammatory proteins.

2.3. Proximal Extension Assay. In the present study we took advantage of the multiplex proximity extension assay (PEA) technology in which a panel of 92 proteins (see Supplementary Table 1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/3874964>) is simultaneously analyzed [18]. The serum samples were assessed with Proseek Multiplex Inflammation I (Olink Bioscience, Uppsala, Sweden) using the PEA according to the manufacturer's instructions. Briefly, 3 μ L incubation mix containing two PEA probes, that is, antibodies equipped with single strand DNA oligonucleotide, against each protein was mixed with 1 μ L serum and the mixture was incubated at 8°C overnight. The mixture was then mixed with 96 μ L extension mix containing PEA enzyme and PCR reagents and incubated for 5 min at room temperature before the plate was transferred to a thermal cycler for 17 cycles of DNA amplification. A 96.96 Dynamic Array IFC (Fluidigm, CA, USA) was prepared and primed according to the manufacturer's instructions. 2.8 μ L of sample mixture was mixed with 7.2 μ L detection mix in a new 96-well plate and 5 μ L was loaded into the right side of the primed 96.96 Dynamic Array IFC. The unique primer pairs for each cytokine were loaded into the left side of the 96.96 Dynamic Array IFC, and the protein expression program was run in Fluidigm Biomark reader according to the instructions for Proseek.

2.4. Statistics. For the baseline characteristics, the Kolmogorov-Smirnov test was applied to test for normality. Unpaired Student's *t*-test was chosen to compare mean values for normally distributed data, whereas for nonnormally distributed data the mean values were compared by a nonparametric two-sided Mann-Whitney *U* test. Pearson Chi-square test was used to analyze the frequency of baseline categorical variables between the high and low pain group.

In order to identify differentially expressed serum proteins between the two groups of patients, protein-level analyses for each individual biomarker were performed. For a group of patients, the protein expression levels of some proteins were below the laboratory's limit of detection (LoD). Therefore, we used a multiple linear regression model with LoD imputed values in place of below-LoD values to test the differences between the groups.

TABLE 1: Baseline characteristics of patients grouped in the high and low pain group.

	Low pain	High pain	<i>p</i> value
Gender, men/women (%)	11/11(50/50)	12/11 (52/48)	0.884 ^a
Age, mean (SD)	40 (9)	41 (12)	0.697 ^b
Current smoker, yes/no (%)	6/16 (27/73)	13/10 (57/43)	0.047 ^a
Treatment, surgery/conservative (%)	10/12 (45/55)	8/15 (35/65)	0.465 ^a
HSCL total score, mean (SD)	1.53 (0.41)	2.09 (0.56)	0.001 ^c

^aPearson Chi-square, ^bunpaired Student's *t*-test, and ^cMann-Whitney *U* test. SD: standard deviation, and HSCL: Hopkins symptom checklist.

Because of the difficulties associated with analyzing data with a high proportion of below-LoD values [20–22], only proteins for which the proportion of below-LoD values was less than 20% were included in the analyses. The false discovery rate (FDR) was controlled using the procedure of Benjamini and Hochberg (1995) [19]. The difference in expression levels was estimated by computing the ratio of the group medians on the original non-log scale.

The linear discriminant analysis [23, 24] was performed to visualize the differences between the two groups. Using vector notation and letting \mathbf{x}_{ij} denote the vector of protein measurements of patient j in group i (with $i = 1$ corresponding to high pain and $i = 2$ corresponding to low pain), $\bar{\mathbf{x}}_i$ denote the sample mean vector in group i , and n_i denote the number of patients in group i , the discriminant score for each individual was computed as

$$(\bar{\mathbf{x}}_1 - \bar{\mathbf{x}}_2)' \left(\sum_{i=1}^2 \sum_{j=1}^{n_i} (\mathbf{x}_{ij} - \bar{\mathbf{x}}_i) (\mathbf{x}_{ij} - \bar{\mathbf{x}}_i)' \right)^{-1} \cdot \left(\mathbf{x}_{ij} - \frac{1}{2} (\bar{\mathbf{x}}_1 + \bar{\mathbf{x}}_2) \right). \quad (1)$$

This resulted in a score, essentially based on a weighted average of the differentially expressed proteins, such that positive values indicated high levels of inflammatory proteins and negative values indicated low levels of inflammatory proteins.

The weighted protein score was visualized in a simple dot plot where each patient was represented by one dot. A positive score indicated a high inflammatory activity, whereas a negative score indicated a low inflammatory activity.

3. Results

The high pain group had more pain when they arrived at the hospital, at 6 weeks and 12-month follow-up, than the low pain group (Figure 1). More smoking and higher HSCL score were also observed in the high pain group (Table 1). Therefore, smoking and HSCL were corrected for in the further analyses, that is, in the multiple linear regression model to test the differences between the high and low pain group.

The analyses of the levels of 92 proteins showed 76 proteins for which at most 20% of the patients had expression




FIGURE 1: Intensity of pain in 45 disc herniation patients recruited from Oslo University Hospital, Ullevål, Norway. The patients were divided into two groups based on their clinical outcome measured by VAS at 12-month follow-up. The data are shown as mean \pm SD.

levels below the LoD. Among these 76 proteins, we identified 41 with $FDR < 0.10$ and 13 with $FDR < 0.05$, which were considered upregulated in the patients with severe pain one year after disc herniation (Table 2). The analyses of the inflammation-related protein levels showed increased expression of many proteins in the high pain group compared to the low pain group.

On the top of the list ranked by estimated increase we found C-X-C motif chemokine 5 (CXCM5; 217% increase), epidermal growth factor (EGF; 142% increase), and monocyte chemoattractant protein 4 (MCP-4; 70% increase).

For each patient, an inflammation score, that is, weighted average of the 41 protein levels, was also constructed. Notably, the two groups were completely separated; all high pain patients had positive scores, whereas all low pain patients had negative scores (Figure 2). Thus, an inflammatory fingerprint in the serum of the patients with persistent lumbar radicular pain after disc herniation was demonstrated. The data showed a clear increase in cytokine levels in the patients that developed chronic pain (Figure 3).

4. Discussion

In the present study, we examined the serum levels of 92 inflammatory proteins in patients one year after lumbar disc herniation. Among these, 41 proteins with $FDR < 0.10$, including IL-6 and IL-8, seemed to be upregulated in the chronic pain patients compared to the patients that fully recovered within one year. Hence, in accordance with our earlier ELISA findings from the same cohort where IL-6 and IL-8 in almost all patients were increased the first weeks after disc herniation [17, 25], the present data showed that patients that develop long lasting radicular pain may be different from patients that recover with regard to measurable cytokines in serum. Moreover, a clear overall difference in the serum cytokine profile between the chronic and the recovered patients was demonstrated.

TABLE 2: List of biomarkers which are significantly differentially expressed when the false discovery rate (FDR) is 0.10 and 0.05. The rightmost column shows the estimated increase on the original non-log scale.

Biomarker	<i>p</i> value	FDR adjusted <i>p</i> value	Estimated increase
MCP-3/CCL7	0.0006	0.047	50.6%
M-CSF/CSF-1	0.001	0.047	20.2%
VEGF-A	0.0015	0.047	47.6%
CXCL10/IP10	0.0017	0.047	55.2%
MCP-2	0.0023	0.047	56.6%
CXCL5	0.0024	0.047	217.0%
CCL-4	0.0034	0.047	43.4%
IL-15-R-alpha	0.0036	0.047	15.2%
MCP-4	0.004	0.047	69.9%
TGF-beta-1	0.0041	0.047	52.3%
CASP-8	0.0051	0.047	14.3%
EGF	0.0064	0.047	142.0%
STAMPB	0.0071	0.047	40.4%
IFNg	0.0102	0.0553	25.0%
IL-6	0.0118	0.0596	68.5%
TRAIL	0.0119	0.0596	16.6%
LIGHT-TNFSF14	0.0147	0.0656	35.6%
CX3CL1	0.0147	0.0656	18.5%
CXCL6	0.0153	0.0656	82.4%
CXCL9-MIG	0.0165	0.0656	39.7%
SIRT2	0.0173	0.0656	44.9%
IL-10-R-beta	0.0179	0.0656	19.6%
MCP-1-CCL2	0.0191	0.0656	36.2%
HGF	0.0195	0.0656	37.9%
Eotaxin-1	0.0198	0.0656	31.3%
AXIN1	0.021	0.0656	11.2%
CCL19	0.0217	0.0656	44.0%
CDCP1	0.0223	0.0656	26.7%
CD40	0.0233	0.0656	18.8%
IL-8	0.0238	0.0656	47.5%
SULT1A1	0.0256	0.0656	21.0%
Beta-NGF	0.0286	0.0679	11.8%
OSM	0.0298	0.0685	78.7%
CCL20	0.0298	0.0685	43.7%
TWEAK-TNFSF12	0.0316	0.0687	21.7%
EIF4EBP1	0.0339	0.0716	59.2%
MIP-1-alpha-CCL3	0.0384	0.0788	16.1%
CXCL11	0.0384	0.0788	54.6%
IL12B	0.0386	0.0788	28.9%
IL18R1	0.0436	0.0828	20.8%
CXCL1	0.0459	0.0852	52.8%

FDR < 0.05

FDR < 0.10

Many of the upregulated proteins with FDR < 0.05 were chemokines and other molecules associated with inflammation, activation of macrophages, and/or immune responses including regulators of glial cells. For example, C-X-C motif chemokine 5 (CXCL5) is a neutrophil chemoattractant which increases the expression of several proinflammatory mediators [26]. Moreover, monocyte chemotactic proteins 2, 3, and

4 (MCP-2, MCP-3/CCL7, and MCP-4) recruit macrophages [27], whereas C-X-C motif chemokine 10 (CXCL10/IP10) activates T-cells [28] and microglia [29]. Macrophages and microglia cells may also be activated by macrophage colony stimulating factor (M-CSF/CSF-1) thought to be upregulated in nucleus pulposus tissue after disc herniation [10, 30].




FIGURE 2: Linear discriminant analysis. An inflammation score was computed for each patient as a weighted average of the protein expression levels for the 41 biomarkers (FDR < 0.10). The scores were adjusted so that positive values indicate an ongoing inflammation and negative values indicate lack of inflammation. The scores are plotted for all patients (patient ID 1–45) in the study.

Several of the upregulated proteins with FDR < 0.05 have also previously been linked to healing and tissue regeneration. C-C motif chemokine 4 (CCL4) that reduces the expression of TNF and IL-1 β [31] may be involved in nucleus pulposus resorption after disc herniation [32]. Vascular endothelial growth factor A (VEGF-A) supports healing, regeneration, and revascularization [33–35] and facilitates opening of the blood-nerve-barrier [36]. Interleukin-15 receptor- α (IL-15R α) is expressed in monocytes, NK cells, and T-cells [37].

In addition, some of the upregulated proteins with FDR < 0.05 may induce cell differentiation, apoptosis, and neuronal loss and influence cell cycle regulation. Epidermal growth factor (EGF) stimulates cell growth, proliferation, and differentiation [38]. Moreover, transforming growth factor β (TGF β) has important immune-regulative role and may reverse inflammation [39], whereas caspase-8 (CASP-8) is involved in FAS mediated apoptosis [40, 41] and cleavage of cytoskeletal proteins. STAM-binding protein (STAMPB) is a zinc metalloprotease involved in cell cycle regulation recently linked to the neuronal loss underlying microcephaly-capillary malformation syndrome [42].

4.1. Methodological Considerations. In PEA, each target molecule is recognized by a pair of affinity binders in which both have to bind the same target molecule prior to signal amplification via qPCR. Similar to other proximity assays [43, 44], the PEA technology also has an increased assay specificity. The specificity of the assay has been validated using a complete pool of PEA probes to analyze either all or submixes of eight antigens, for which significant signal over background was obtained only when the cognate antigen was present [18]. As previously described, the PEA technology has a sensitivity in low pM range [18].

Still, as some of the protein expressions were below the LoD, the actual expression levels of these proteins remain unknown. As high proportions of below-LoD measurements lead to tests with low power, we opted to only analyze the proteins for which the proportion of below-LoD measurements was at most 20%. Moreover, the two groups were balanced in terms of age, sex, and treatment but differed in smoking habits and HSCL scores (Table 1). Our linear regression model was therefore adjusted for smoking and HSCL scores to exclude the possibility that any differences found actually were due to differences in smoking and HSCL.

In the present study, we examined 92 serum proteins. Thus, the analyses of the data include multiple testing, that is, associated with many challenges. Clearly, we cannot control the family wise error rate by Bonferroni correction as such corrections tend to be far too conservative, resulting in statistical procedures with very low power. However, since this is a study where the focus is on evaluation of the methodology (proof of concept), a limited rate of false positives is acceptable. We therefore controlled the false discovery rate using the procedure of Benjamini and Hochberg [19].

Given a FDR of 0.10 and 0.05, up to 1/10 and 1/20 of our findings are likely to be false positives. Importantly, however, almost all inflammatory markers moved in the same direction. Moreover, although a few false positive markers may be present, our study clearly demonstrated that inflammatory profiling can be used to characterize chronic sciatica patients. The present data also showed that the PEA is a reliable and sensitive method to study proteins in serum associated with clinical measures.

Despite the above mentioned challenges, the linear discriminant analysis demonstrated a clear difference between the high pain group and the low pain group. A weighted average of the differentially expressed proteins with FDR < 0.10 was used [24]. This allowed us to summarize our multivariate data in a single objective measure [19]. Notably, the two groups were completely separated; all high pain patients had positive scores, whereas all low pain patients had negative scores. Thus, even though there might be one or two false positive markers, an inflammatory fingerprint in the serum of the patients that developed persistent lumbar radicular pain after disc herniation was defined by the PEA technology.

4.2. Study Limitations. Although the present study had a prospective design when it comes to the pain ratings, the serum protein levels of the patients were only measured at one time point, that is, 12 months after disc herniation. Thus, it is hard to tell whether the observed differences in serum proteins are a trait or a state of the patients that develop chronic pain. Moreover, medication and other life style factors may also influence the serum protein levels. However, the analgesics and anti-inflammatory-drugs taken by the patients were higher in the high pain group than in the low pain group. Therefore, it seems likely that the effect of medication reduces rather than increases the difference in inflammatory serum proteins. Nevertheless, the results demonstrated that it is possible to detect differences between persistent and nonpersistent pain patients. The fact that this




FIGURE 3: The expression of the 13 most significant proteins (FDR < 0.05). All 45 patients were included. The data are shown by box plot; median and IQR ± min/max.

protein pattern can be detected in serum suggests that the PEA technology may have a clinical potential.

5. Conclusion

In summary, the present data demonstrated that sciatica patients with a chronic outcome have increased levels of inflammatory proteins in serum one year after disc herniation. This is to our knowledge the first protein serum profiling study of patients with chronic lumbar radicular pain. An inflammatory PEA-based fingerprint of these persistent pain patients was demonstrated. We conclude that serum proteins may be measurable molecular markers of patients that develop persistent pain after disc herniation. The pathophysiological relevance of these proteins, however, remains to be investigated.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

Acknowledgments

This research project was supported by Uppsala Berzelii Technology Centre for Neurodiagnostics, with financing from the Swedish Governmental Agency for Innovation Systems (Vinnova) and the Swedish Research Council (Grant no. P29797-1). The present study also received financial support from the South Eastern Norway Regional Health Authority (Grant no. 2013/20589). The authors thank Elina I. Schistad and Anette Storesund for data collection.

References

- [1] R. A. Deyo and Y.-J. Tsui-Wu, "Functional disability due to back pain. A population-based study indicating the importance of socioeconomic factors," *Arthritis & Rheumatism*, vol. 30, no. 11, pp. 1247–1253, 1987.
- [2] M. Younes, I. Béjia, Z. Aguir et al., "Prevalence and risk factors of disk-related sciatica in an urban population in Tunisia," *Joint Bone Spine*, vol. 73, no. 5, pp. 538–542, 2006.
- [3] J.-P. Valat, S. Genevay, M. Marty, S. Rozenberg, and B. Koes, "Sciatica," *Best Practice & Research: Clinical Rheumatology*, vol. 24, no. 2, pp. 241–252, 2010.
- [4] F. Balagué, M. Nordin, A. Sheikhzadeh et al., "Recovery of severe sciatica," *Spine*, vol. 24, no. 23, pp. 2516–2524, 1999.
- [5] R. F. McCarron, M. W. Wimpee, P. G. Hudkins, and G. S. Laros, "The inflammatory effect of nucleus pulposus: a possible element in the pathogenesis of low-back pain," *Spine*, vol. 12, no. 8, pp. 760–764, 1987.
- [6] K. Olmarker, J. Blomquist, J. Strömberg et al., "Inflammatogenic properties of nucleus pulposus," *Spine*, vol. 20, no. 6, pp. 665–669, 1995.
- [7] H. Anzai, M. Hamba, A. Onda, S. Konno, and S. Kikuchi, "Epidural application of nucleus pulposus enhances nociceptive responses of rat dorsal horn neurons," *Spine*, vol. 27, no. 3, pp. E50–E55, 2002.
- [8] H. Brisby and I. Hammar, "Thalamic activation in a disc herniation model," *Spine*, vol. 32, no. 25, pp. 2846–2852, 2007.
- [9] J. M. Cuellar, P. X. Montesano, J. F. Antognini, and E. Carstens, "Application of nucleus pulposus to L5 dorsal root ganglion in rats enhances nociceptive dorsal horn neuronal windup," *Journal of Neurophysiology*, vol. 94, no. 1, pp. 35–48, 2005.
- [10] N. G. Egeland, A. Moen, L. M. Pedersen, H. Brisby, and J. Gjerstad, "Spinal nociceptive hyperexcitability induced by experimental disc herniation is associated with enhanced local expression of Csf1 and FasL," *Pain*, vol. 154, no. 9, pp. 1743–1748, 2013.
- [11] T. Takebayashi, J. M. Cavanaugh, A. Cüneyt Özakay, S. Kallakuri, and C. Chen, "Effect of nucleus pulposus on the neural activity of dorsal root ganglion," *Spine*, vol. 26, no. 8, pp. 940–944, 2001.
- [12] P. Andrade, G. Hoogland, M. A. Garcia, H. W. Steinbusch, M. A. Daemen, and V. Visser-Vandewalle, "Elevated IL-1b and IL-6 levels in lumbar herniated discs in patients with sciatic pain," *European Spine Journal*, vol. 22, no. 4, pp. 714–720, 2013.
- [13] J. D. Kang, M. Stefanovic-Racic, L. A. McIntyre, H. I. Georgescu, and C. H. Evans, "Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Contributions of nitric oxide, interleukins, prostaglandin E2, and matrix metalloproteinases," *Spine*, vol. 22, no. 10, pp. 1065–1073, 1997.
- [14] H. Takahashi, T. Suguro, Y. Okazima, M. Motegi, Y. Okada, and T. Kakiuchi, "Inflammatory cytokines in the herniated disc of the lumbar spine," *Spine*, vol. 21, no. 2, pp. 218–224, 1996.
- [15] N. Üçeyler, J. P. Rogausch, K. V. Toyka, and C. Sommer, "Differential expression of cytokines in painful and painless neuropathies," *Neurology*, vol. 69, no. 1, pp. 42–49, 2007.
- [16] A. Geiss, E. Varadi, K. Steinbach, H. W. Bauer, and F. Anton, "Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy," *Neuroscience Letters*, vol. 237, no. 2-3, pp. 65–68, 1997.
- [17] L. M. Pedersen, E. Schistad, L. M. Jacobsen, C. Røe, and J. Gjerstad, "Serum levels of the pro-inflammatory interleukins 6 (IL-6) and -8 (IL-8) in patients with lumbar radicular pain due to disc herniation: a 12-month prospective study," *Brain, Behavior, and Immunity*, vol. 46, pp. 132–136, 2015.
- [18] E. Assarsson, M. Lundberg, G. Holmquist et al., "Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability," *PLoS ONE*, vol. 9, no. 4, Article ID e95192, 2014.
- [19] Y. Benjamini and Y. Hochberg, "Controlling the false discovery rate: a practical and powerful approach to multiple testing," *Journal of the Royal Statistical Society Series B (Methodological)*, vol. 57, no. 1, pp. 289–300, 1995.
- [20] D. R. Helsel, "More than obvious: better methods for interpreting nondetect data," *Environmental Science & Technology*, vol. 39, no. 20, pp. 419A–423A, 2005.
- [21] D. R. Helsel, *Statistics for Censored Environmental Data Using Minitab and R*, vol. 77, John Wiley & Sons, New York, NY, USA, 2011.
- [22] D. Zhang, C. Fan, J. Zhang, and C.-H. Zhang, "Nonparametric methods for measurements below detection limit," *Statistics in Medicine*, vol. 28, no. 4, pp. 700–715, 2009.
- [23] R. A. Fisher, *The Use of Multiple Measurements in Taxonomic Problems*, vol. 7 of *Annals of Eugenics*, 1936.
- [24] R. A. Johnson and D. W. Wichern, *Applied Multivariate Statistical Analysis*, Prentice Hall, Englewood Cliffs, NJ, USA, 6th edition, 2007.

- [25] E. I. Schistad, A. Espeland, L. M. Pedersen, L. Sandvik, J. Gjerstad, and C. Røe, "Association between baseline IL-6 and 1-year recovery in lumbar radicular pain," *European Journal of Pain*, vol. 18, no. 10, pp. 1394–1401, 2014.
- [26] B. Chandrasekar, P. C. Melby, H. M. Sarau et al., "Chemokine-cytokine cross-talk: the ELR⁺ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF- κ B pathway," *The Journal of Biological Chemistry*, vol. 278, no. 7, pp. 4675–4686, 2003.
- [27] T. Kimura, S. Kobayashi, F. Hanihara-Tatsuzawa, A. Sayama, T. MaruYama, and T. Muta, "Responses of macrophages to the danger signals released from necrotic cells," *International immunology*, vol. 26, no. 12, pp. 697–704, 2014.
- [28] D. D. Taub, A. R. Lloyd, K. Conlon et al., "Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells," *The Journal of Experimental Medicine*, vol. 177, no. 6, pp. 1809–1814, 1993.
- [29] G. Flynn, S. Maru, J. Loughlin, I. A. Romero, and D. Male, "Regulation of chemokine receptor expression in human microglia and astrocytes," *Journal of Neuroimmunology*, vol. 136, no. 1-2, pp. 84–93, 2003.
- [30] M. Sawada, A. Suzumura, H. Yamamoto, and T. Marunouchi, "Activation and proliferation of the isolated microglia by colony stimulating factor-1 and possible involvement of protein kinase C," *Brain Research*, vol. 509, no. 1, pp. 119–124, 1990.
- [31] F. Saika, N. Kiguchi, Y. Kobayashi, Y. Fukazawa, and S. Kishioka, "CC-chemokine ligand 4/macrophage inflammatory protein-1 β participates in the induction of neuropathic pain after peripheral nerve injury," *European Journal of Pain*, vol. 16, no. 9, pp. 1271–1280, 2012.
- [32] H. Haro, K. Shinomiya, H. Komori et al., "Upregulated expression of chemokines in herniated nucleus pulposus resorption," *Spine*, vol. 21, no. 14, pp. 1647–1652, 1996.
- [33] H. Haro, T. Kato, H. Komori, M. Osada, and K. Shinomiya, "Vascular endothelial growth factor (VEGF)-induced angiogenesis in herniated disc resorption," *Journal of Orthopaedic Research*, vol. 20, no. 3, pp. 409–415, 2002.
- [34] S. I. Nikolaev, A. R. Gallyamov, G. V. Mamin, and Y. A. Chelyshev, "Poly(ϵ -caprolactone) nerve conduit and local delivery of *vegf* and *fgf2* genes stimulate neuroregeneration," *Bulletin of Experimental Biology and Medicine*, vol. 157, no. 1, pp. 155–158, 2014.
- [35] F. Zor, M. Deveci, A. Kilic et al., "Effect of *vegf* gene therapy and hyaluronic acid film sheath on peripheral nerve regeneration," *Microsurgery*, vol. 34, no. 3, pp. 209–216, 2014.
- [36] T. K. Y. Lim, X. Q. Shi, H. C. Martin et al., "Blood-nerve barrier dysfunction contributes to the generation of neuropathic pain and allows targeting of injured nerves for pain relief," *Pain*, vol. 155, no. 5, pp. 954–967, 2014.
- [37] C. Bergamaschi, J. Bear, M. Rosati et al., "Circulating IL-15 exists as heterodimeric complex with soluble IL-15R α in human and mouse serum," *Blood*, vol. 120, no. 1, pp. e1–e8, 2012.
- [38] Y. Shirakata, T. Komurasaki, H. Toyoda et al., "Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes," *The Journal of Biological Chemistry*, vol. 275, no. 8, pp. 5748–5753, 2000.
- [39] M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and R. A. Flavell, "Transforming growth factor- β regulation of immune responses," *Annual Review of Immunology*, vol. 24, pp. 99–146, 2006.
- [40] D. Han, Y. Ding, S.-L. Liu et al., "Double role of Fas ligand in the apoptosis of intervertebral disc cells in vitro," *Acta Biochimica et Biophysica Sinica*, vol. 41, no. 11, pp. 938–947, 2009.
- [41] J.-B. Park, H. Chang, and K.-W. Kim, "Expression of Fas ligand and apoptosis of disc cells in herniated lumbar disc tissue," *Spine*, vol. 26, no. 6, pp. 618–621, 2001.
- [42] L. M. McDonell, G. M. Mirzaa, D. Alcantara et al., "Mutations in STAMBP, encoding a deubiquitinating enzyme, cause microcephaly-capillary malformation syndrome," *Nature Genetics*, vol. 45, no. 5, pp. 556–562, 2013.
- [43] S. Darmanis, R. Y. Nong, M. Hammond et al., "Sensitive plasma protein analysis by microparticle-based proximity ligation assays," *Molecular and Cellular Proteomics*, vol. 9, no. 2, pp. 327–335, 2010.
- [44] S. Darmanis, R. Y. Nong, J. Vänelid et al., "ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing," *PLoS ONE*, vol. 6, no. 9, Article ID e25583, 2011.